IBSA
17.3.2022 15:42:11 CET | Business Wire | Press release
Challenge, resilience, courage, nature, innovation. These are the keywords that characterise Sailing into the Future. Together , the new international project that sees IBSA (Institut Biochimique SA) the protagonist of a new three-year enterprise, which starts in 2022, albeit with a long-term vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005863/en/
“The project we are launching today is a real sporting endeavour, which sees us compete in some of the world’s most prestigious and challenging regattas”, stated Arturo Licenziati, President, CEO and Founder of IBSA . “This new project, however, is not only an ocean crossing, but also an opportunity to tell the values of IBSA, increasing its visibility around the world. In fact, IBSA is today an international company that maintains a vision that is always aimed at the future and ready to face challenges that go well beyond the therapeutic and personal care areas ”.
Founded in 1945 and headquartered in Lugano (Switzerland), IBSA is a leading scientific, economic and industrial reality in the pharmaceutical sector, thanks to the design outlined by Arturo Licenziati. A multinational company employing 2,000 people – including headquarters, subsidiaries and production sites – IBSA is present with its products in over 90 countries on 5 continents, with 16 subsidiaries located in Europe, China and the United States and with a turnover of over CHF 700 million.
“Innovating by keeping people at the core of our ecosystem, without ever setting limits: those are the horizons of the IBSA Group, which has always been inspired by the desire to go further ”, explained Licenziati . “ Sailing into the future. Together is a metaphor for our corporate history, but also a wish to grow and change, to find new means to offer health, well-being and new perspectives for the communities within which we operate, through social and environmental sustainability ”.
The project Sailing into the Future. Together engaged a team of great experience and sporting talent, involved right from the design and building phase of an innovative Class40 boat that will be led by Alberto Bona , the skipper who has been entrusted with the task of transforming this undertaking into a success.
“The Route du Rhum is the first stage of a three-year project: it’s one of the most challenging solo regattas in the world, as well as one of the most popular events in international ocean sailing. The project relies on a competent and greatly experienced team, while the conceptual design of the boat and its construction are entrusted to a successful duo: thus, we have all the credentials to put a winning boat in the water. The further challenge will be to make the most of the time available after the July launch, and carry out the in-water test part to make it reliable and performing ”, commented Alberto Bona . “Naturally, I thank our sponsor IBSA, with which I share the taste for the challenge, for continuous improvement, and the desire to break through new horizons. IBSA has chosen sailing to represent strength, determination, innovation, but also to raise awareness about a greater respect for nature, with a view to sustainability ”.
Beyond sport, and in a broader perspective, sailing is part of a path that brings the Company ever closer to the topic of sustainability , promoting respect for nature and the environment, but also to a new sensitivity and awareness about issues of collective responsibility , with activities in favour of people in difficulty or with disabilities.
“As part of this project, we decided to be a partner of some nautical clubs, in order to support inclusive sailing initiatives. We started a collaboration with the Yacht Club of Punta Ala (GR), to which we donated two boats for disabled children, to involve them in experiences in close contact with the sea, enabling them to navigate with accessible boats and compete in integrated races ”, explained Giorgio Pisani, Vice President Southern Europe and Project Leader . “The goal is to create an actual inclusion of the disabled on the competition field, promoting social integration as well as opportunities for dialogue, interaction and mutual understanding, thus helping break down barriers and differences ”.
The Company will also receive a prize during the award ceremony of the first edition (2022) of the Sport for Nature Awards – to be held today, March 17, 2022 – an event that aims to celebrate the “sport with a green soul”.
The award Azienda per il sociale: IBSA per la vela inclusiva (“Company for social initiatives: IBSA for inclusive sailing”) will be assigned precisely for raising awareness in favour of social and environmental sustainability through the values of sport, and in particular of sailing, as a means for social inclusion.
To narrate all the phases of the project Sailing into the Future. Together and accompany its development, the new website www.ibsasailing.com was created, also available in Italian and French . From here, it will be possible to follow the journey of skipper Alberto Bona, find out more about the Route du Rhum , the team and the new Class40 boat, that will set sail on November 6 from Saint-Malo, headed towards the island of Guadeloupe. In addition, the site will host photo and video content and news relating to IBSA’s social responsibility initiatives.
IBSA
IBSA (Institut Biochimique SA) is a multinational pharmaceutical Swiss Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 16 subsidiaries located in Europe, China and the United States. The company has a consolidated turnover of over 700 million Swiss francs, and employs 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents and others in development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardio-metabolic, respiratory, consumer health. It is also one of the four largest operators worldwide in the area of Reproductive Medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on 4 pillars: Person, Innovation, Quality and Responsibility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005863/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom